## Kaleb Michaud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4957346/publications.pdf

Version: 2024-02-01

191 papers

13,883 citations

23567 58 h-index 22166 113 g-index

196 all docs

 $\begin{array}{c} 196 \\ \\ \text{docs citations} \end{array}$ 

196 times ranked 11908 citing authors

#	Article	IF	CITATIONS
1	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis and Rheumatism, 2011, 63, 573-586.	6.7	864
2	Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti–tumor necrosis factor therapy in 18,572 patients. Arthritis and Rheumatism, 2004, 50, 1740-1751.	6.7	787
3	Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Research and Therapy, 2009, 11, 229.	3.5	682
4	Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care and Research, 2012, 64, 640-647.	3.4	566
5	Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis and Rheumatism, 2007, 56, 2886-2895.	6.7	498
6	Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease-modifying antirheumatic drugs, and anti–tumor necrosis factor therapy. Arthritis and Rheumatism, 2006, 54, 628-634.	6.7	422
7	Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis and Rheumatism, 2004, 50, 372-379.	6.7	382
8	Comorbidities in rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2007, 21, 885-906.	3.3	333
9	Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti–tumor necrosis factor therapy. American Journal of Medicine, 2004, 116, 305-311.	1.5	331
10	The effect of methotrexate and anti–tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON‥EARS of observation. Arthritis and Rheumatism, 2007, 56, 1433-1439.	6.7	327
11	Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. Rheumatology International, 2017, 37, 1551-1557.	3.0	313
12	Direct medical costs and their predictors in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2003, 48, 2750-2762.	6.7	238
13	Development and validation of the health assessment questionnaire II: A revised version of the health assessment questionnaire. Arthritis and Rheumatism, 2004, 50, 3296-3305.	6.7	231
14	Predicting mortality in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2003, 48, 1530-1542.	6.7	224
15	Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQâEII), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality Measures of Theumatoid arthritis disease activity. Patient (PtCA) and Provider (PtCA) Global	3.4	223
16	Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score With 28â€Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Scoreâ€I (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity	3.4	202
17	Indexâ€5. Arthritis Care and Research, 2011, 63, S14-36. Fibromyalgia diagnosis: A comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis and Rheumatism, 2006, 54, 169-176.	6.7	181
18	Validation of the Rheumatic Disease Comorbidity Index. Arthritis Care and Research, 2015, 67, 865-872.	3.4	177

#	Article	IF	CITATIONS
19	Rheumatoid Factor as a Potentiator of Anti–Citrullinated Protein Antibody–Mediated Inflammation in Rheumatoid Arthritis. Arthritis and Rheumatology, 2014, 66, 813-821.	<b>5.</b> 6	174
20	Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize ra patients with fibromyalgia. Journal of Rheumatology, 2004, 31, 695-700.	2.0	169
21	A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries. Seminars in Arthritis and Rheumatism, 2010, 40, 2-14.e1.	3.4	161
22	Predicting depression in rheumatoid arthritis: The signal importance of pain extent and fatigue, and comorbidity. Arthritis and Rheumatism, 2009, 61, 667-673.	6.7	160
23	2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. Arthritis Care and Research, 2019, 71, 1540-1555.	3.4	157
24	Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. Journal of Rheumatology, 2005, 32, 2130-5.	2.0	155
25	The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case–control analysis. Arthritis and Rheumatism, 2008, 58, 2612-2621.	6.7	142
26	Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care and Research, 2012, 64, 668-674.	3.4	132
27	Minimal disease activity for rheumatoid arthritis: a preliminary definition. Journal of Rheumatology, 2005, 32, 2016-24.	2.0	132
28	Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the <scp>COVID</scp> â€19 Pandemic. ACR Open Rheumatology, 2020, 2, 335-343.	2.1	131
29	Chronic Conditions and Health Problems in Rheumatic Diseases: Comparisons with Rheumatoid Arthritis, Noninflammatory Rheumatic Disorders, Systemic Lupus Erythematosus, and Fibromyalgia. Journal of Rheumatology, 2010, 37, 305-315.	2.0	123
30	Resistance of rheumatoid arthritis patients to changing therapy: Discordance between disease activity and patients' treatment choices. Arthritis and Rheumatism, 2007, 56, 2135-2142.	6.7	113
31	The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Rheumatology, 2011, 50, 16-24.	1.9	113
32	Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales. Journal of Rheumatology, 2006, 33, 1942-51.	2.0	111
33	Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy. Journal of Rheumatology, 2007, 34, 1674-83.	2.0	109
34	Effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthritis Care and Research, 2012, 64, 1471-1479.	3.4	108
35	Impact of Total Shoulder Arthroplasty on Generic and Shoulder-Specific Health-Related Quality-of-Life Measures. Journal of Bone and Joint Surgery - Series A, 2012, 94, e127.	3.0	105
36	Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: A nested, case–control study. Arthritis and Rheumatism, 2008, 59, 1090-1096.	6.7	104

#	Article	IF	CITATIONS
37	Causeâ€Specific Mortality in Male US Veterans With Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 36-45.	3.4	103
38	Mortality in fibromyalgia: A study of 8,186 patients over thirtyâ€five years. Arthritis Care and Research, 2011, 63, 94-101.	3.4	93
39	Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open, 2019, 5, e000935.	3.8	92
40	EQ-5D and SF-36 Quality of Life Measures in Systemic Lupus Erythematosus: Comparisons with Rheumatoid Arthritis, Noninflammatory Rheumatic Disorders, and Fibromyalgia. Journal of Rheumatology, 2010, 37, 296-304.	2.0	91
41	Risk of COVIDâ€19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in Atâ€Risk Individuals. Arthritis and Rheumatology, 2021, 73, 2179-2188.	5.6	89
42	A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). Journal of Rheumatology, 2005, 32, 2410-5.	2.0	88
43	Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1292-1297.	0.9	86
44	Weight Loss, the Obesity Paradox, and the Risk of Death in Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 1711-1717.	5.6	84
45	Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1089-1098.	5.6	83
46	Biologic drugs for rheumatoid arthritis in the medicare program: A costâ€effectiveness analysis. Arthritis and Rheumatism, 2008, 58, 939-946.	6.7	82
47	Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. Rheumatology, 2011, 50, 101-109.	1.9	80
48	Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. Journal of Rheumatology, 2007, 34, 696-705.	2.0	77
49	Remission of rheumatoid arthritis in clinical practice: Application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis and Rheumatism, 2011, 63, 3204-3215.	6.7	75
50	Medications associated with fracture risk in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, 1041-1047.	0.9	75
51	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nature Communications, 2016, 7, 12460.	12.8	73
52	Performance of the Patientâ€Reported Outcomes Measurement Information System 29â€Item Profile in Rheumatoid Arthritis, Osteoarthritis, Fibromyalgia, and Systemic Lupus Erythematosus. Arthritis Care and Research, 2017, 69, 1312-1321.	3.4	71
53	Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 848-854.	0.9	64
54	Work disability and its economic effect on 55-64-year-old adults with rheumatoid arthritis. Arthritis and Rheumatism, 2005, 53, 603-608.	6.7	62

#	Article	IF	Citations
55	Rheumatology Informatics System for Effectiveness: A National Informaticsâ€Enabled Registry for Quality Improvement. Arthritis Care and Research, 2016, 68, 1866-1873.	3.4	61
56	Household income and earnings losses among 6,396 persons with rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 1875-83.	2.0	61
57	Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. Journal of Bone and Mineral Research, 2013, 28, 984-991.	2.8	60
58	Associations of Hydroxychloroquine Use With Lipid Profiles in Rheumatoid Arthritis: Pharmacologic Implications. Arthritis Care and Research, 2014, 66, 1619-1626.	3.4	60
59	Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients. Journal of Rheumatology, 2005, 32, 1006-12.	2.0	59
60	The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: Discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis and Rheumatism, 2005, 52, 3873-3879.	6.7	58
61	Validity and Reliability Problems with Patient Global as a Component of the ACR/EULAR Remission Criteria as Used in Clinical Practice. Journal of Rheumatology, 2012, 39, 1139-1145.	2.0	57
62	Impact of Obesity and Adiposity on Inflammatory Markers in Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2017, 69, 1789-1798.	3.4	56
63	Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: A systematic literature review and meta-analysis. Seminars in Arthritis and Rheumatism, 2019, 49, 358-365.	3.4	56
64	The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. Journal of Rheumatology, 2021, 48, 648-655.	2.0	56
65	Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis and Rheumatism, 2007, 57, 935-942.	6.7	54
66	Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials. Arthritis Care and Research, 2016, 68, 1478-1488.	3.4	54
67	The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis Research and Therapy, 2010, 12, R35.	3.5	52
68	Mortality Risk by Functional Status and Health-related Quality of Life in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2012, 39, 54-59.	2.0	51
69	Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 583-9.	2.0	50
70	The Hawthorne Effect, Sponsored Trials, and the Overestimation of Treatment Effectiveness. Journal of Rheumatology, 2010, 37, 2216-2220.	2.0	47
71	Prospective study of posttraumatic stress disorder and disease activity outcomes in US veterans with rheumatoid arthritis. Arthritis Care and Research, 2013, 65, 227-234.	3.4	46
72	The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. Journal of Rheumatology, 2007, 34, 2211-7.	2.0	46

#	Article	IF	Citations
73	A Mobile App With Optical Imaging for the Self-Management of Hand Rheumatoid Arthritis: Pilot Study. JMIR MHealth and UHealth, 2018, 6, e12221.	3.7	45
74	Anemia and renal function in patients with rheumatoid arthritis. Journal of Rheumatology, 2006, 33, 1516-22.	2.0	44
75	Polysymptomatic Distress in Patients With Rheumatoid Arthritis: Understanding Disproportionate Response and Its Spectrum. Arthritis Care and Research, 2014, 66, 1465-1471.	3.4	43
76	Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study. Arthritis Research and Therapy, 2019, 21, 141.	3.5	43
77	International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. Arthritis Care and Research, 2019, 71, 1556-1565.	3.4	43
78	Using technology to support clinical care and research in rheumatoid arthritis. Current Opinion in Rheumatology, 2018, 30, 276-281.	4.3	41
79	Development and initial validation of a selfâ€assessed lupus organ damage instrument. Arthritis Care and Research, 2010, 62, 559-568.	3.4	40
80	The problem of rheumatoid arthritis disease activity and remission in clinical practice. Journal of Rheumatology, 2008, 35, 1015-22.	2.0	40
81	Strong Association of Health Literacy With Functional Status Among Rheumatoid Arthritis Patients: A Crossâ€Sectional Study. Arthritis Care and Research, 2014, 66, 508-514.	3.4	39
82	A PROMIS Measure of Neuropathic Pain Quality. Value in Health, 2016, 19, 623-630.	0.3	39
83	Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Diseaseâ€Modifying Antirheumatic Drugs. ACR Open Rheumatology, 2019, 1, 424-432.	2.1	39
84	2019 American College of Rheumatology Recommended Patientâ€Reported Functional Status Assessment Measures in Rheumatoid Arthritis. Arthritis Care and Research, 2019, 71, 1531-1539.	3.4	39
85	Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: A longitudinal study of 18,485 patients. Arthritis Care and Research, 2011, 63, 366-372.	3.4	37
86	Impact of Total Knee Arthroplasty as Assessed Using Patientâ€Reported Pain and Healthâ€Related Quality of Life Indices: Rheumatoid Arthritis Versus Osteoarthritis. Arthritis and Rheumatology, 2015, 67, 2503-2511.	5.6	37
87	Body Mass Index, Weight Loss, and Causeâ€Specific Mortality in Rheumatoid Arthritis. Arthritis Care and Research, 2018, 70, 11-18.	3.4	35
88	Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2021, 73, 1606-1616.	3.4	35
89	Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015. Annals of the Rheumatic Diseases, 2021, 80, 286-292.	0.9	35
90	Outâ€ofâ€pocket expenses and their burden in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2009, 61, 1563-1570.	6.7	34

#	Article	IF	CITATIONS
91	Converting modified health assessment questionnaire (HAQ), multidimensional HAQ, and HAQII scores into original HAQ scores using models developed with a large cohort of rheumatoid arthritis patients. Arthritis Care and Research, 2010, 62, 1481-1488.	3.4	34
92	Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects. Arthritis Research and Therapy, 2011, 13, R168.	3.5	34
93	Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?. RMD Open, 2015, 1, e000155-e000155.	3.8	34
94	Changes in Body Mass Related to the Initiation of Diseaseâ€Modifying Therapies in Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1818-1827.	5.6	34
95	Validity and Responsiveness of a 10â€Item Patientâ€Reported Measure of Physical Function in a Rheumatoid Arthritis Clinic Population. Arthritis Care and Research, 2017, 69, 338-346.	3.4	32
96	Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patientâ€Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus. ACR Open Rheumatology, 2020, 2, 53-60.	2.1	32
97	Outcome and Predictor Relationships in Fibromyalgia and Rheumatoid Arthritis: Evidence Concerning the Continuum versus Discrete Disorder Hypothesis. Journal of Rheumatology, 2009, 36, 831-836.	2.0	31
98	Patient-Reported Outcomes in Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 2016, 42, 219-237.	1.9	29
99	Associations of toll-like receptor (TLR)-4 single nucleotide polymorphisms and rheumatoid arthritis disease progression: An observational cohort study. International Immunopharmacology, 2015, 24, 346-352.	3.8	28
100	Correlation of the Multiâ€Biomarker Disease Activity Score With Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Metaâ€Analysis. Arthritis Care and Research, 2019, 71, 1459-1472.	3.4	28
101	Rheumatoid arthritis patients are not at increased risk for 30-day cardiovascular events, infections, or mortality after total joint arthroplasty. Arthritis Research and Therapy, 2013, 15, R195.	3.5	27
102	Costâ€Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 1751-1757.	3.4	27
103	Mobile Apps for Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 2019, 45, 197-209.	1.9	27
104	Allopurinol Dose Escalation and Mortality Among Patients With Gout. Arthritis and Rheumatology, 2018, 70, 1298-1307.	5.6	26
105	Persistence and Dose Escalation of Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. Journal of Rheumatology, 2014, 41, 1935-1943.	2.0	25
106	Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme. RMD Open, 2017, 3, e000498.	3.8	25
107	The impact of menopause on functional status in women with rheumatoid arthritis. Rheumatology, 2018, 57, 798-802.	1.9	24
108	Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 1261-6.	2.0	24

#	Article	IF	CITATIONS
109	The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis. Journal of Managed Care & Decialty Pharmacy, 2018, 24, 4-11.	0.9	23
110	Obesity, Weight Loss, and Progression of Disability in Rheumatoid Arthritis. Arthritis Care and Research, 2018, 70, 1740-1747.	3.4	22
111	Adaptation of American College of Rheumatology Rheumatoid Arthritis Disease Activity and Functional Status Measures for Telehealth Visits. Arthritis Care and Research, 2021, 73, 1809-1814.	3.4	22
112	Proposed Metrics for the Determination of Rheumatoid Arthritis Outcome and Treatment Success and Failure. Journal of Rheumatology, 2009, 36, 27-33.	2.0	21
113	Patient's experience of psoriatic arthritis: a conceptual model based on qualitative interviews. RMD Open, 2020, 6, e001321.	3.8	21
114	2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Care and Research, 2022, 74, 1399-1408.	3.4	21
115	Malondialdehyde–acetaldehyde antibody concentrations in rheumatoid arthritis and other rheumatic conditions. International Immunopharmacology, 2018, 56, 113-118.	3.8	20
116	Prevalence, risk, and risk factors for oral and ocular dryness with particular emphasis on rheumatoid arthritis. Journal of Rheumatology, 2008, 35, 1023-30.	2.0	20
117	Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure. Journal of Clinical Rheumatology, 2018, 24, 203-209.	0.9	19
118	Chronic lung disease in U.S. Veterans with rheumatoid arthritis and the impact on survival. Clinical Rheumatology, 2018, 37, 2907-2915.	2.2	19
119	Development of Resilience Among Rheumatoid Arthritis Patients: A Qualitative Study. Arthritis Care and Research, 2020, 72, 1257-1265.	3.4	19
120	Outcomes of a Mobile App to Monitor Patientâ€Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis and Rheumatology, 2021, 73, 1421-1429.	5.6	19
121	How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. Annals of the Rheumatic Diseases, 2016, 75, 1789-1796.	0.9	18
122	Rheumatoid Arthritis Patients' Motivations for Accepting or Resisting Diseaseâ€Modifying Antirheumatic Drug Treatment Regimens. Arthritis Care and Research, 2018, 70, 533-541.	3.4	18
123	Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial. Rheumatology and Therapy, 2019, 6, 409-419.	2.3	18
124	The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy. Annals of Internal Medicine, 2021, 174, 1510-1518.	3.9	18
125	Scale Characteristics and Mapping Accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2010, 37, 1615-1625.	2.0	17
126	Associations of Circulating Cytokines and Chemokines With Cancer Mortality in Men With Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 2394-2402.	5.6	17

#	Article	IF	Citations
127	Utilization of Care Outside the Veterans Affairs Health Care System by US Veterans With Rheumatoid Arthritis. Arthritis Care and Research, 2017, 69, 776-782.	3.4	17
128	Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries. Arthritis Care and Research, 2015, 67, 1637-1645.	3.4	16
129	Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. Advances in Therapy, 2016, 33, 1347-1359.	2.9	16
130	Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. Annals of the Rheumatic Diseases, 2016, 75, 1797-1805.	0.9	16
131	Deriving common comorbidity indices from the MedDRA classification and exploring their performance on key outcomes in patients with rheumatoid arthritis. Rheumatology, 2018, 57, 548-554.	1.9	15
132	Trends and Determinants of Osteoporosis Treatment and Screening in Patients With Rheumatoid Arthritis Compared to Osteoarthritis. Arthritis Care and Research, 2018, 70, 713-723.	3.4	15
133	Incidence, Prevalence, and Burden of Gout in the Veterans Health Administration. Arthritis Care and Research, 2021, 73, 1363-1371.	3.4	15
134	Self-Management of Rheumatoid Arthritis: Mobile Applications. Current Rheumatology Reports, 2021, 23, 2.	4.7	15
135	Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. Journal of Rheumatology, 2004, 31, 355-8.	2.0	15
136	Estimation of Minimally Important Differences and Patient Acceptable Symptom State Scores for the Patientâ∈Reported Outcomes Measurement Information System Pain Interference Short Form in Rheumatoid Arthritis. ACR Open Rheumatology, 2020, 2, 320-329.	2.1	14
137	Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis. Rheumatology, 2015, 54, 1640-1649.	1.9	13
138	Increasing Public Health Burden of Arthritis and Other Rheumatic Conditions and Comorbidity: Results From a Statewide Health Surveillance System, 2007–2012. Arthritis Care and Research, 2016, 68, 1417-1427.	3.4	13
139	Changes in Alcohol Use and Associations With Disease Activity, Health Status, and Mortality in Rheumatoid Arthritis. Arthritis Care and Research, 2020, 72, 301-308.	3.4	13
140	Knee joint unloading and daily physical activity associate with cartilage T2 relaxation times 1 month after ACL injury. Journal of Orthopaedic Research, 2022, 40, 138-149.	2.3	13
141	A Novel Mobile App and Population Management System to Manage Rheumatoid Arthritis Flares: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e84.	1.0	13
142	The National Data Bank for Rheumatic Diseases (NDB). Clinical and Experimental Rheumatology, 2016, 34, S100-S101.	0.8	13
143	Risk factors for venous thromboembolism and atherosclerotic cardiovascular disease: do they differ in patients with rheumatoid arthritis?. RMD Open, 2021, 7, e001618.	3.8	12
144	Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry. Rheumatology International, 2021, 41, 1755-1761.	3.0	12

#	Article	IF	Citations
145	Changes in Diseaseâ€Modifying Antirheumatic Drug Treatment for Patients With Rheumatoid Arthritis in the US During the COVIDâ€19 Pandemic: A Threeâ€Month Observational Study. Arthritis Care and Research, 2021, 73, 1322-1331.	3.4	12
146	2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis and Rheumatology, 2022, 74, 1464-1473.	5.6	12
147	Realâ€World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis. ACR Open Rheumatology, 2019, 1, 560-570.	2.1	11
148	Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs. Advances in Therapy, 2019, 36, 1337-1357.	2.9	11
149	Increase in Cannabis Use Among Adults With Rheumatic Diseases: Results From a 2014–2019 United States Observational Study. Arthritis Care and Research, 2022, 74, 2091-2099.	3.4	10
150	Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. PLoS ONE, 2018, 13, e0205013.	2.5	9
151	Measures of Rheumatoid Arthritis Disease Activity. Arthritis Care and Research, 2020, 72, 4-26.	3.4	9
152	Obesity and the Risk of Incident Chronic Opioid Use in Rheumatoid Arthritis. Arthritis Care and Research, 2021, 73, 1405-1412.	3.4	9
153	All-cause and cause-specific mortality in persons with fibromyalgia and widespread pain: An observational study in 35,248 persons with rheumatoid arthritis, non-inflammatory rheumatic disorders and clinical fibromyalgia. Seminars in Arthritis and Rheumatism, 2020, 50, 1457-1464.	3.4	9
154	Patterns of Tumor Necrosis Factor Inhibitor (TNF i) Biosimilar Use Across United States Rheumatology Practices. ACR Open Rheumatology, 2020, 2, 79-83.	2.1	8
155	Driving Ability and Safety in Rheumatoid Arthritis: A Systematic Review. Arthritis Care and Research, 2021, 73, 489-497.	3.4	8
156	Associations of Alcohol Use with Radiographic Disease Progression in African Americans with Recent-onset Rheumatoid Arthritis. Journal of Rheumatology, 2013, 40, 1498-1504.	2.0	7
157	<p>Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient</p> . ClinicoEconomics and Outcomes Research, 2019, Volume 11, 117-128.	1.9	7
158	Probiotic Use and Psoriatic Arthritis Disease Activity. ACR Open Rheumatology, 2020, 2, 330-334.	2.1	7
159	Reduction of Cardiovascular Disease and Mortality Versus Risk of Newâ€Onset Diabetes Mellitus With Statin Use in Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2023, 75, 597-607.	3.4	7
160	Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. Pharmacoepidemiology and Drug Safety, 2015, 24, 1121-1132.	1.9	6
161	Systematic Review and Appraisal of the Crossâ€Cultural Validity of Functional Status Assessment Measures in Rheumatoid Arthritis. Arthritis Care and Research, 2020, 72, 798-805.	3.4	6
162	Acceptability and Content Validity of Patientâ€Reported Outcome Measures Considered From the Perspective of Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2021, 73, 510-519.	3.4	6

#	Article	IF	CITATIONS
163	Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry. Arthritis Care and Research, 2023, 75, 231-239.	3.4	6
164	OPEX: Development of a novel overall patient experience measure to facilitate interpretation of comparison effectiveness studies. PLoS ONE, 2021, 16, e0245598.	2.5	6
165	Data collection, maintenance, and analysis for rheumatic disease research. Rheumatic Disease Clinics of North America, 2004, 30, 753-768.	1.9	5
166	The challenges of determining RA disease activity and remission in clinical practice. Nature Clinical Practice Rheumatology, 2008, 4, 462-463.	3.2	5
167	Timing and Impact of Decisions to Adjust Diseaseâ€Modifying Antirheumatic Drug Therapy for Rheumatoid Arthritis Patients With Active Disease. Arthritis Care and Research, 2018, 70, 834-841.	3.4	5
168	Is It Time to Banish Composite Measures for Remission in Rheumatoid Arthritis?. Arthritis Care and Research, 2019, 71, 1300-1303.	3.4	5
169	Posttraumatic Stress Disorder, Depression, Anxiety, and Persistence of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis. ACR Open Rheumatology, 2020, 2, 555-564.	2.1	4
170	Defining Pain That Does Not Interfere With Activities Among Rheumatoid Arthritis Patients. Arthritis Care and Research, 2021, 73, 626-632.	3.4	4
171	The Impact of Asthma and Chronic Obstructive Pulmonary Disease (COPD) on Patientâ€Reported Outcomes in Systemic Lupus Erythematosus (SLE). ACR Open Rheumatology, 2021, 3, 221-230.	2.1	4
172	Reply. Arthritis Care and Research, 2013, 65, 835-835.	3.4	2
173	FRIO463â€ENTHESITIS, DACTYLITIS, AND AXIAL DISEASE IN PSORIATIC ARTHRITIS (PSA): IMPACT ON PATIENT QUALITY OF LIFE AND WORK PRODUCTIVITY. , 2019, , .		2
174	Response to: †Medications associated with fracture risk in patients with rheumatoid arthritis' by Chen et al. Annals of the Rheumatic Diseases, 2019, 80, annrheumdis-2019-216293.	0.9	2
175	OP0226â€SOLID TUMOUR OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARD RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY., 2019,,.	S:	2
176	FRIO118â€INFECTION OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDS: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY. , 2019, , .		2
177	Vehicle Control as a Measure of Realâ€World Driving Performance in Patients with Rheumatoid Arthritis. Arthritis Care and Research, 2021, , .	3.4	2
178	Response to: †Statin therapy now more common than steroids in clinical practice' by Pareek and Chankurdar. Annals of the Rheumatic Diseases, 2017, 76, e19-e19.	0.9	1
179	Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 1268-1280.	0.9	1
180	Defining Minimally Important Changes for the Patient Activity Scaleâ€I. Arthritis Care and Research, 2020, 73, 1456-1460.	3.4	1

#	Article	IF	CITATIONS
181	Diabetes-Related Complications and Costs in Medicare Beneficiaries with Comorbid Rheumatoid Arthritis and Diabetes Treated with Abatacept Versus Other Targeted DMARDs. Rheumatology and Therapy, 2022, 9, 1091-1107.	2.3	1
182	Rheumatoid arthritis and heart failure: The reply. American Journal of Medicine, 2004, 117, 709.	1.5	0
183	Modelling the cost-effectiveness of statin therapy in rheumatoid arthritis: a Markov-cycle evaluation from national data bank for rheumatic diseases. Journal of Pharmaceutical Health Services Research, 2017, 8, 139-145.	0.6	0
184	O09. ECONOMIC BURDEN OF RHEUMATOID ARTHRITIS IS HIGHER FOR ANTI-CITRULLINATED PROTEIN ANTIBODY: POSITIVE PATIENTS. Rheumatology, 2017, 56, .	1.9	0
185	The Interface Between Digital Health and Rheumatology. Rheumatic Disease Clinics of North America, 2019, 45, xv-xvi.	1.9	0
186	SAT0377â€DIFFERENCES IN CLINICAL CHARACTERISTICS, QUALITY OF LIFE, DISABILITY, AND WORK PRODUCT IN PSORIATIC ARTHRITIS PATIENTS BY GENDER: FINDINGS FROM A CROSS-SECTIONAL SURVEY IN THE US AND EUROPE., 2019,,.	IVITY	0
187	Response to:  Association of proton pump inhibitors with fracture risk in patients with rheumatoid arthritis' by Sugiyama. Annals of the Rheumatic Diseases, 2020, 79, e111-e111.	0.9	0
188	Reply. Arthritis Care and Research, 2020, 72, 1340-1340.	3.4	0
189	Reply. Arthritis Care and Research, 2020, 72, 1509-1510.	3.4	0
190	Response to: â€~Association between proton pump inhibitors therapy and fracture risk in patients with rheumatoid arthritis' by Lai <i>et al</i> . Annals of the Rheumatic Diseases, 2020, 79, e157-e157.	0.9	0
191	Reply. Arthritis Care and Research, 2020, 72, 736-738.	3.4	O